Search the Newsreel

CelLBxHealth study detects drug targets on cancer cells rivals would miss - UPDATE

ETFs Investing in Omnicell, Inc. Stocks

This article lists various ETFs that hold Omnicell, Inc. (OC9) stocks, sorted by market value. It provides key details for each ETF, such as issuer, management style, focus, expense ratio, AUM, price, change, and 3-year NAV total return. The ETFs predominantly target small-cap and …

Understanding the Setup: (TIGO) and Scalable Risk

This article analyzes Millicom International Cellular S.a. (NASDAQ: TIGO), highlighting a weak near-term sentiment but strong long-term outlook. It identifies an exceptional 28.9:1 risk-reward setup, targeting an 8.4% gain versus 0.3% risk. The piece outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk …

Millicom Intl Cellular Market Sentiment

This article provides an overview of market sentiment for Millicom International Cellular (TIGO), detailing analyst consensus, short interest, options flow, and insider activity. It highlights an "Equal-Weight" analyst consensus with a target price of $61, rising short interest, and more bullish options flow. The …

UKGI Data Breach Puts Cellebrite Stock And Cybersecurity Shares In Focus

A recent data breach at UK Government Investments has highlighted cybersecurity risks for companies linked to government and financial infrastructure. This article examines three stocks from Simply Wall St's Cybersecurity Stocks screener: Cellebrite DI (CLBT), Catapult Sports (ASX:CAT), and Intapp (INTA), discussing their relevance, …

ETFs Investing in Turkcell Iletisim Hizmetleri A.S. Sponsored ADR Stocks

This article lists several ETFs that invest in Turkcell Iletisim Hizmetleri A.S. Sponsored ADR stocks, providing details such as market value, weight, issuer, management style, expense ratio, AUM, price, change percentage, relative volume, and 3-year NAV total return. The ETFs listed aim to make …

CLRB Q1 2026 Earnings: 32.4% EPS Beat Signals Cost Discipline Amid Pipeline Progress - Banking Earnings Report

FuelCell Energy Number of Employees 2026 | Employee Count & Headcount Data

FuelCell Energy, Inc. (FCEL) had approximately 417 employees worldwide as of March 2026, representing a 22.0% decline from 2023. The company is actively hiring with 15 job postings in 2026, though new postings have significantly decreased. The workforce is primarily concentrated in the United …

AbCellera Biologics (ABCL) Signs Vertex Deal, Is The Stock Still Cheap?

AbCellera Biologics (ABCL) has signed a new collaboration with Vertex Pharmaceuticals for autoimmune disease treatments. Despite a recent share price rebound, the stock remains undervalued according to Simply Wall St's narrative, suggesting a fair value of $10.43 compared to its last close of $5.71. …

Price to earnings forward of Omnicell, Inc. – NASDAQ:OMCL

This article provides financial information for Omnicell, Inc. (NASDAQ: OMCL), specifically focusing on its forward price-to-earnings ratio. It lists the company's stock market details, financial overview, and acknowledges the data sources used.

Cellectis (CLLS) to Post Quarterly Earnings on Thursday

Cellectis (CLLS) is scheduled to report its H1 2026 earnings after market close on Thursday, August 6th, with analysts forecasting a loss of $0.263 per share and revenue of $11.05 million. The biotechnology company previously reported an EPS loss of $0.18, beating estimates, but …

Lineage Cell Therapeutics (LCTX) to Post Earnings on Thursday

FuelCell Energy (NASDAQ:FCEL) Rating Increased to Hold at Wall Street Zen

Wall Street Zen has upgraded FuelCell Energy (NASDAQ:FCEL) from a "sell" to a "hold" rating, though overall analyst sentiment remains mixed, resulting in an average "Hold" rating and a consensus price target of $22.83. The company recently reported a quarterly loss of $0.53 per …

Enterprise value to EBITDA forward of FuelCell Energy, Inc. – NASDAQ:FCEL

This article provides financial data for FuelCell Energy, Inc. (NASDAQ: FCEL), specifically focusing on its enterprise value to EBITDA forward metric. It lists the company's market and financial information, indicating that the market was closed at the time of publication and no trades were …

BriaCell Therapeutics Corp Revenue Breakdown – TSX:BCT

Cellectar Biosciences, Inc. Revenue Breakdown – NASDAQ:CLRB

This article provides a revenue breakdown for Cellectar Biosciences, Inc. (NASDAQ: CLRB) as presented on TradingView. It offers an overview of the company's financial data, including statements, statistics, dividends, earnings, and segment performance. The information is sourced from various financial data providers like ICE …

FuelCell Energy (OTCPK:FCEL.B) - Stock Analysis

This report provides a stock analysis for FuelCell Energy (OTCPK:FCEL.B), highlighting its valuation, future growth prospects, past performance, financial health, and dividend information. The company is currently unprofitable but forecasts revenue growth, and has recently introduced a 12.5 MW power block solution for data …

Omnicell (OMCL) Stock Falls As Tariff Boost Clouds Profit Strength

Omnicell's stock fell 4.7% despite beating non-GAAP earnings guidance, largely due to a one-time tariff refund. While the company emphasizes its transition to recurring revenue through services and strategic products, bears highlight execution risks, volatile product bookings, and the impact of non-recurring items on …

Is Omnicell Inc (OMCL) a Bargain After 4.7% Drop? GF Value Says Undervalued

Omnicell Inc (OMCL) shares dropped 4.7%, bringing its price to $35.37, which is 8.9% below its GF Value™ of $38.82, suggesting it is undervalued. The company's GF Score™ is 75/100, with strong valuation but weak growth. Despite the undervaluation, recent insider selling and mixed …

FuelCell Energy Inc (FCEL) Shares Fall 8.5% -- What GF Score of 55 Tells Investors

FuelCell Energy Inc (FCEL) shares dropped 8.5% to $21.61, indicating it is 196.4% overvalued according to GuruFocus' GF Value of $7.29. The company's GF Score of 55/100 suggests average performance, with strong growth potential but weak profitability and valuation. Despite insider net buying, investors …

Scancell Holdings Plc Revenue Breakdown – LSE:SCLP

Celldex Therapeutics (CLDX) After Phase 2 Trial Results As Valuation Questions Come Into Focus

Celldex Therapeutics (CLDX) is under scrutiny following its Phase 2 clinical trial results for prurigo nodularis. The stock has seen significant momentum with strong share price returns over the last year, leading to questions about its valuation. While it trades at a discount compared …

Omnicell (OMCL) Stock Trades Down, Here Is Why

Omnicell (OMCL) stock fell 9.9% in the afternoon session after the company issued weak guidance for the upcoming quarter, despite reporting strong second-quarter results that beat Wall Street's expectations. The projected third-quarter revenue of approximately $304 million was 2.9% below analysts' estimates, and earnings …

OMCL Q2 Earnings Call Highlights Titan XT Pipeline Growth

Omnicell, Inc. OMCL highlighted accelerating customer engagement around its next-generation medication management platforms during its second-quarter 2026 earnings call while noting that large customer decisions are taking longer to finalize. Management emphasized strong demand for Titan XT and OmniSphere but reduced the lower end …

Cellectis SA expected to post a loss of 26 cents a share - Earnings Preview

Cellectis SA is projected to report a loss of 26 cents per share, according to an earnings preview. This forecast comes from Refinitiv and is being highlighted by TradingView News.

OMNICELL INC. : WELLS FARGO CUTS TARGET PRICE TO $50 FROM $55

Wells Fargo has reduced its target price for OMNICELL INC. (OMCL.O) shares from $55 to $50. This change was reported by Reuters on July 31, 2026. The article provides this update without further elaboration or analysis.

BExcellent Appoints Chief Academic Director Ng King Hang as Executive Director to Drive AI-Enabled Expansion

Celldex Therapeutics Inc (CLDX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Celldex Therapeutics Inc (CLDX), noting its current valuation score of 6.88, which ranks 244 out of 385 in the Biotechnology & Medical Research industry. The company's P/E ratio is -8.92, indicating a position between its recent high …

Turkcell Iletisim Hizmetleri AS (TKC) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Turkcell Iletisim Hizmetleri AS (TKC), highlighting its current risk score of 8.10 and its ranking within the Telecommunications Services industry. It details various risk metrics including beta, maximum drawdown, volatility, and liquidity. The assessment indicates TKC tends …

Lineage Cell Therapeutics (LCTX) Holds Above $1.04 Support After 0.90% Pullback - BPI Bull Confirmed

Bexcellent Group Holdings Limited Announces Appointment of Ng King Hang as Executive Director, Effective August 1, 2026

ImmuCell Corp (ICCC) Financial Health: Profitability & Balance Sheet Analysis

ImmuCell Corp (ICCC) has a stable financial status with a current score of 8.98, ranking it 17th out of 155 in the Pharmaceuticals industry. The company demonstrated high operating efficiency with its latest quarterly revenue increasing by 28.39% year-over-year to $10.36M, and net profit …

Cellnex Telecom bestätigt Umsatzprognose für 2026 und 2027

Cellectis Q2 Results: Financials due August 6 after close

Cellectis (NASDAQ: CLLS) will report its Q2 2026 financial results on August 6, 2026, after the close of the US market. The company will not host a conference call to discuss these results, instead making the details available on its investor relations website and …

Cellnex Telecom SA (CLNXF) (Q2 2026) Earnings Call Highlights: Record EBITDAaL Margin and EUR1 ...

This article first appeared on GuruFocus. Revenue: Organic revenue growth of 5% year-on-year, reaching EUR2 billion in the first half of 2026. Adjusted EBITDA: Grew by 6.4% year-on-year. EBITDA after Leases: Grew by 7.7% year-on-year. Recurrent Levered Free Cash Flow: Increased by 11% year-on-year. …

Cellebrite DI Ltd (CLBT) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Cellebrite DI Ltd (CLBT), stating its current valuation score as 7.28, ranking 309 out of 485 in the Software & IT Services industry. The company's current P/E ratio is 50.33, which is significantly above its recent low. …